Neuroendocrine Tumors
Conditions
Keywords
NETs, MTD, Everolimus.
Brief summary
NET originate in neuroendocrine cells throughout the body. The goal of this study is to assess the safety and efficacy of the combination of everolimus and the intravenous radiolabeled Lu-177 DOTATATE Therapy as a 1st line therapy in unresectable well to moderately differentiated metastatic neuroendocrine tumors of all GI, lung and pancreatic origins. This is a phase 1 - 2 study. The phase 1 part involves finding the maximum tolerating dose (MTD) of Everolimus.
Detailed description
Neuroendocrine tumors NET refers to tumors that originate in neuroendocrine cells throughout the body (including in the thymus, lung, pancreas, gastrointestinal \[GI\] tract and less common sites). They can be broadly subclassified into well-differentiated and poorly differentiated cancers. Treatment of well differentiated NET are complex and involves surgical, Locoregional and systemic modalities depending on the manifestations as well as extent of disease. Treatment is best planned in a multidisciplinary tumor board. Of the emerging new systemic modalities are Everolimus and radiolabelled somatostatin analogue. The goal of this study is to assess the safety and efficacy of the combination of everolimus and the intravenous radiolabeled Lu-177 DOTATATE Therapy (a somatostatin analogue) as a first line therapy in unresectable well to moderately differentiated metastatic neuroendocrine tumors of all gastrointestinal, lung and pancreatic origins. This is a phase 1 - 2 study. The phase 1 part involves finding the maximum tolerating dose (MTD) of Everolimus.
Interventions
DRUGEverolimus
Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
Sponsors
King Faisal Specialist Hospital & Research Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years old. * Histologically confirmed well to moderately differentiated neuroendocrine tumors of GI, lung or pancreatic origin. The grading follows the WHO grading system (Appendix III). * Measurable disease by CT or MRI. * Positive Tc-99m Octreotide scan or Ga-68 Octreotate scan (Positive means uptake at tumor sites). * Advanced disease which are not treatable by surgical resection. * Documented progressive disease within the past 12 months. * WHO Performance Status 0 - 2. * Fasting blood sugar ≤ 1.5 Χ Upper Limit of Normal (ULN). * Fasting triglycerides ≤ 2.5 Χ Upper Limit of Normal (ULN), and fasting cholesterol ≤ 300 mg/dl or ≤ 7.75 ml/l. * Adequate renal function with creatinine clearance ≥ 60 ml/l. * Adequate hepatic function: * Total bilirubin ≤ 1.5 Χ Upper Limit of Normal (ULN) * Liver Function Tests (Serum aspartate aminotransferase and alanine transaminase levels) ≤ 2.5 Χ ULN (and ≤ 5 Χ ULN, in case of presence of liver metastasis) * Adequate hematological values: * Absolute neutrophil count ≥ 1 x 109/L * Platelet count ≥ 100 x 109/L * Signed written informed consent before enrolment.
Exclusion criteria
* Readily completely Resectable disease. * Prior therapy with everolimus or systemic chemotherapy. * Prior chemoembolization, radio-embolization, or bland embolization within 6 months before enrolment. Likewise, patients are ineligible if had undergone conventional radiotherapy, radiofrequency ablation, cryoablation or alcohol injection within 1 month prior to enrolment. * Prior long acting somatostatin analogue within 1 month prior to enrolment. Short acting somatostatin analogue is allowed as long as it is not administered within 12 hours before or /and 12 hours after the administration of the intravenous radiolabelled Lu-177 DOTATATE Therapy. * Presence of Central Nervous System metastasis. * Previous malignancy within 5 years, except adequately treated non melanomatous skin cancer or in situ cervical cancer * Other active malignancy. * HIV infection. * Severe or uncontrolled medical conditions, such as: * Active uncontrolled severe infection * History of invasive fungal infection. * Child C liver dysfunction. * Severely impaired lung function. * Psychiatric or mental disorder, precluding understanding of the information of the trial related topics and giving valid informed consent. * Any psychological, familial, geographic or social circumstances which could impair the patient's ability to participate in the trial and comply with follow up. * Treatment with other anti-cancer therapy. * Known hypersensitivity to any of the study drugs. * Pregnant or breast feeding women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of treatment related adverse events | 3 years | Establish safety profile of the combination of everolimus and intravenous radiolabeled Lu-177 DOTATATE |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Survival assessment | 3 years | Progression free survival (PFS) and Overall survival (OS) |
Countries
Saudi Arabia
Contacts
Primary ContactAli Aljubran, MD
Backup ContactShouki Bazarbashi, MD
Outcome results
None listed